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Body ﬂuid biomarkers of CNS damage may help improving the
prognostic and diagnostic accuracy in ischaemic stroke.
Fifty–three patients were included. Stroke severity and outcome
was rated using the NIHSS and modiﬁed Ranking Scale (mRS). Fer-
ritin, S100B and NfH were measured in CSF and serum. Infarct vol-
ume was calculated from T2W images.
CSF S100B (median 1.00 ng/mL) and CSF ferritin (10.0 ng/mL)
levels were elevated in stroke compared to the controls (0.62 ng/mL,
p<0.0001; 2.34 ng/mL, p<0.0001). Serum S100B (0.09 ng/mL) was
higher in stroke compared to the controls (0.01 ng/mL). CSF S100B
levels were higher in patients with a cardio–embolic stroke (2.88 ng/mL)
than in those with small vessel disease (0.89 ng/mL, p<0.05). CSF
S100B levels correlated with the NIHSS on admission (R=0.56, p<0.01)
and the stroke volume (R=0.44, p=0.01). CSF S100B and NfH-SMI35
levels correlated with outcome on the mRS.
CSF S100B levels were related to stroke severity and infarct vol-
ume and highest in in cardio–embolic stroke.Stroke biomarkers 3
1 Introduction
Ischaemic stroke is one of the major causes of death and disability in the
Western population over 60 years of age.1 Transient or permanent occlu-
sion of a blood vessel leads to ischaemic damage to the glial and nerve
cells in the affected vascular territory. There is evidence that glial cells
may be more susceptible to ischaemia than neurons.2–4 Following cellular
disintegration, cell–type speciﬁc proteins are released into the extracellu-
lar ﬂuid (ECF). These proteins pass from the ECF into the cerebrospinal
ﬂuid (CSF) and blood, from where they can be quantiﬁed. In addition to
the immediate release of these proteins from dying cells, some proteins
such as the cytokine S100B will also be actively secreted by glial cells in
response to the brain’s homeostatic imbalance. Similarly ferritin, an iron–
binding protein, will be released by microglia in the presence of iron. Sev-
eral groups have recently called into question the validity of blood S100B
levels as a speciﬁc biomarker for brain damage,5–8 whereas others have
conﬁrmed it.9,10 The main argument of the former group is that S100B is
not present exclusively in astrocytes11 but can also be measured in the
blood of patients who did not suffer from brain injury, such as patients
with critical illness8 and those with systemic trauma.12,13 In contrast, CSF
S100B levels reﬂect more accurately the pathological changes in the cen-Stroke biomarkers 4
tral nervous system (CNS).7 In fact, serum and CSF S100B levels did not
correlate in one study.14 Given the number of studies on levels of serum
S100B in stroke patients,15–24 there is surprisingly little literature on CSF
S100B levels in patients with a well–deﬁned ischaemic stroke. A Medline
search on CSF and S100 revealed 154 hits (25-JUN-2007), yet none was
focused on stroke. Four studies referred to patients with ischaemic brain
injury without providing more clinical details.11,25–27 One patient described
by Anderson et al. developed a stroke following surgery for an aneurysm
of the thoracoabdominal aorta.28 To the best of our knowledge, there are
no published studies on combined CSF and serum S100B levels in a well
deﬁned cohort of patients with an ischaemic cerebrovascular event.
This study was therefore designed to bridge the gap between data on
S100B in the CSF and the serum. We hypothesised that the previously
reported relationship between serum biomarker levels20,22 and infarct vol-
ume, stroke severity and outcome would also exist for CSF levels of the
same biomarkers.
2 Methods
Patients Serum and CSF from 33 patients admitted to the Centre Hospi-
talier Universitaire Vaudois (CHUV) Lausanne with suspicion of ischaemic
stroke was collected prospectively and kept in a hospital CSF bank. AllStroke biomarkers 5
clinical and radiological data was collected prospectively with the clinician
being blinded to the data on the CSF and serum biomarkers. In all cases
the indication for performing a lumbar puncture (LP) was to exclude vas-
culitis. All patients were assessed clinically using the National Institutes of
Health stroke scale (NIHSS) and the modiﬁed Rankin scale (mRS). Clin-
ical outcome was assessed with the mRS at discharge. An mRS score
of 3 to 6 was considered a poor outcome. The study has been approved
by the appropriate local ethics committee and was therefore performed in
accordance with the ethical standards laid down in the 1964 Declaration
of Helsinki.
The control group consisted of 20 non–neurological patients (8 female,
12 male) receiving spinal anesthesia for minor surgery. The median age
of the control group was 33.5 years (IQR 24-54 years).
Sample collection and analysis The CSF samples were collected and
time–matched. The samples were coded and anonymised. The CSF was
centrifuged (2500 rpm) and the supernatant stored at -80◦C until analysis.
The concentrations of S100B, ferritin and NfHSMI35 were analyzed us-
ing previously–described ELISA techniques.14,29–31 The analyst was blinded
to all other clinical or radiological information. All data were exchanged be-
tween the centers prior to breaking the code.Stroke biomarkers 6
Reference values For rigorism this study used previously published ref-
erence limits in addition to the control group. The control group of non–
neurological patients allowed for quantiﬁcation of all three biomarkers from
the same CSF sample, which was assumed to be completely normal.
However, the use CSF from neurologically normal patients does po-
tentially introduce a bias with artiﬁcially low CSF biomarker levels, with
a statistical signiﬁcant but clinically irrelevant result. For this reason we
made additional use of the previously published normal ranges for the CSF
biomarkers, which were derived from our own large reference populations
(n=388 to 41614,29,31) using exactly the same in–house developed assays.
If CSF biomarkers were above the published upper limit of normal then
they were regarded as pathological (high).
MRI analysis MRI for ﬁnal infarct volume calculation was usually per-
formed within 2 weeks of symptom onset using a Siemens Magnetom Vi-
sion 1.5 Tesla MRI-scanner with echo-planar imaging. T2-images were
obtained using turbo spin echo, with a matrix of 192x256, slice thickness
of 5 mm, echo/repetition time of 3800/90, and a gap of 1.5 mm. The in-
farcted cerebral areas on the T2W images were manually traced on each
slice. These values were then added and multiplied by the slice-thickness
in order to obtain volumetric values which were expressed in cubic cen-Stroke biomarkers 7
timeters (cm3). In four patients, ﬁnal stroke volumes were calculated us-
ing plain CT between day 2 and 14 after stroke onset. The radiological
assessment was done blinded to any of the clinical or biomarker data.
Statistical analysis Statistical analysis was performed using SAS soft-
ware. Independent variables were compared using the non-parametric
two-sample exact Wilcoxon rank-sum test for two variables and a two–way
unbalanced ANOVA (general linear model) for more than two variables,
followed by multivariate analysis when appropriate. The linear relationship
between continuous variables was evaluated using the Spearman correla-
tion coefﬁcient. The ordinal NIHSS was treated as a linear variable in the
regression models. The level of signiﬁcance for the multiple correlations
was corrected using the Bonferroni method. The 2–test and Fisher’s ex-
act test were used for comparing proportions of patients. Two–tailed tests
were used throughout and a p–value of <0.05 was accepted as signiﬁcant.
3 Results
The patient characteristics are presented in Table 1. In addition to is-
chaemic stroke due to cardio–embolic, large- or small vessel disease,
there was one patient each with p–ANCA vasculitis (n=1), herpes zoster
vasculitis (n=1), anti–phospholipid antibodies (n=1) and malignancy (n=1).Stroke biomarkers 8
There was no correlation of the patients age with either the NIHSS on
admission or at discharge, or with the mRS.
CSF biomarker levels The CSF S100B (p<0.0001) and ferritin (p<0.0001)
levels were signiﬁcantly higher in patients suffering from a stroke when
compared to the non–neurological control group (Table 2). No such differ-
ence was found for CSF NfHSMI35 levels.
These results were conﬁrmed using our upper reference values (Table
3). Eighty–two percent of the stroke patients had elevated CSF S100B
levels. Thirty–nine percent of the stroke patients had elevated CSF ferritin
levels. One patient suffered from a haemorrhagic transformation two days
after his ischaemic stroke and the LP was performed about 24 hours after
the event. This patient had CSF ferritin levels over 10–fold higher (150
ng/mL) than the upper reference limit (12 ng/mL). Only 7% of the stroke
patients had elevated CSF NfHSMI35 levels.
There were no correlations between any of the CSF biomarkers with
age or the time delay from onset of stroke to lumbar puncture (median
3 days, range 1 to 15 days). The median CSF total protein, CSF:serum
albumin quotient (Qalb, white and red cell count were in the normal range
(Table 1). An elevated total protein was found in 12, an elevated Qalb in
14, an elevated white cell count in 3 and an elevated red cell count in 9Stroke biomarkers 9
patients. There were no correlations between any of the CSF biomarker
with either the CSF total protein, Qalb, CSF white or red cell count.
Serum biomarker levels The median serum S100B levels were higher
in patients with stroke compared to non–neurological controls (p<0.0001).
In contrast serum NfHSMI35 levels were higher in the control group (p<0.05).
As for the CSF, there were no correlations between any of the serum
biomarkers with age or the time delay from onset of stroke to venopunc-
ture.
Relationship between CSF and serum biomarkers In stroke patients,
there was a weak correlation between the CSF NfHSMI35 and serum levels
(R=0.40, p=0.03), but not between the CSF and the serum S100B levels
(R=0.14, p=0.42). In the control group there was no correlation between
CSF and serum levels for either S100B (R=0.02, p=0.9) or NfHSMI35 (R=0.05,
p=0.8).
Aetiology Because of small numbers for some causes (see Table 1),
this particular study included only patients with cardio–embolic, and large-
and small–vessel disease (Table 1).
There was a signiﬁcant difference in CSF S100B levels between the
three main causes (F2;20=4.5, p=0.025). The post–hoc analysis showedStroke biomarkers 10
this to be caused by signiﬁcantly higher CSF S100B levels in patients with
cardio–embolic stroke (median 2.88 ng/mL) compared to those with small–
vessel disease (0.89 ng/mL, p=0.014, Figure 1) and large–vessel disease
(0.44 ng/mL, p=0.031). A multivariate analysis was also performed be-
cause cardio–embolic strokes are known to have a larger infarct volume
than those from small–vessel disease. Importantly, the signiﬁcance re-
mained after correcting for infarct volume (F=10.2, p=0.017). In contrast
to the CSF S100B levels, the stroke volume alone did not distinguish be-
tween the main aetiologies (F2;20=3.3, p=0.06).
Similar to the CSF, serum NfHSMI35 (F2;20=5.04, p=0.017) but not serum
S100B distinguished between the main aetiologies. The post–hoc analy-
sis demonstrated that serum NfHSMI35 levels were signiﬁcantly higher in
patients with stroke due to large–vessel pathology (median 0.15 ng/mL)
when compared to those with small–vessel pathology (median 0.00 ng/mL,
p=0.004). However, in contrast to the ﬁnding for CSF S100B levels, sig-
niﬁcance was lost for the serum S100B levels after correcting for infarct
volume (F=0.07, p=0.93).
Vascular territory The affected vascular territories are shown in Table 1.
There was no relationship between the affected vascular territory and the
CSF and serum S100B, ferritin or NfHSMI35 levels (data not shown).Stroke biomarkers 11
Stroke volume The median volume of all strokes was 4 cm3 (see Ta-
ble 1). The ischaemia volume correlated weakly with the CSF S100B lev-
els (R=0.44, p=0.01) and the NIHSS on admission (R=0.56, p<0.01). The
data are shown in Figure 2 on a logarithmic scale because of a cluster
of small volume strokes (< 5 cm3). The smallest stroke volume related to
high CSF S100B levels (>0.55 ng/mL) was 0.5 cm3. The other biomarkers
were not related to stroke volume.
Stroke severity on admission The median NIHSS score on admission
was 4 (see Table 1). There was a signiﬁcant correlation between CSF
S100B levels and the NIHSS on admission (R=0.56, p<0.001, Figure 3).
No such correlation with the NIHSS was found for CSF NfHSMI35 or ferritin
levels or the serum levels of S100B and NfHSMI35 .
Outcome As expected, there was a strong correlation between the NIHSS
on admission with the NIHSS at discharge (R=0.77, p<0.0001) and the
mRS at discharge (R=0.75, p<0.0001).
With regard to the biomarkers, a weak correlation with the mRS on
discharge was found with the CSF NfHSMI35 (R=0.37, p=0.049) and CSF
S100B levels (R=0.36, p=0.039) as well as with the stroke volume (R=0.39,
p=0.026). The degree of improvement in the NIHSS did correlate inverselyStroke biomarkers 12
with the CSF S100B levels (R=-0.5, p=0.0035).
Because the samples were collected at different time points, a partial
correlation with the time delay as a co-variate was performed. Signiﬁcance
remained for the correlation between the mRS on discharge and CSF
S100B levels (R=0.49, p=0.01) and the stroke volume (R=0.40, p=0.039),
but was lost for CSF NfHSMI35 (R=0.35, p=0.07). As before, patients with
higher CSF S100B levels showed less improvement on the NIHSS than
those with lower CSF S100B levels (R=-0.45, p=0.018).
4 Discussion
The main ﬁndings of this study were increased levels of S100B and ferritin
in the CSF of a substantial number of patients suffering from an ischaemic
stroke. Increased CSF S100B levels were found in 82% of these patients
and were signiﬁcantly higher than in the control population. The highest
levels were present in patients who suffered from an ischaemic cardio–
embolic stroke (Figure 1 and Table 3). CSF S100B levels did correlated
with the clinical severity of stroke on admission (NIHSS, R=0.56, Figure 3).
Additionally, CSF S100B levels but not serum S100B levels were related
to outcome expressed either as the level of improvement on the NIHSS
or as the mRS on discharge. Although this suggests that CSF S100B
levels may be more sensitive than serum S100B levels, it needs to beStroke biomarkers 13
borne in mind that most patients in the present study only suffered from
a minor ischaemic stroke, and a larger amount of CNS tissue destruction
may have brought to light a relationship between the serum S100B levels
and outcome as demonstrated by others who investigated patients with a
more severe ischaemic stroke.19–22,32,33
An increase in CSF ferritin levels was observed in 39% of patients with
an ischaemic stroke (Table 3). The highest level was found in the CSF of
one patient two days following a haemorrhagic transformation (CSF fer-
ritin 150 ng/mL, CSF total protein 1.5 g/L, CSF red cells 2768, CSF white
cells 23). There is as yet no literature available on longitudinal ferritin lev-
els in the CSF of patients who have suffered haemorrhagic strokes. The
biological function of ferritin is to bind and transport iron. Ferritin is ac-
tively produced by microglia in response to any free iron within the central
nervous system. Following an intracranial or subarachnoid bleed erythro-
cytes haemolyse and the released haemoglobin is metabolised. During
this process iron is liberated, ferritin binds this toxic element and delivers
it back to the intra cellular department.34 CSF ferritin levels appear to be a
reliable indicator of a haemorrhagic transformation, but with the increasing
availability of brain imaging facilities, the clinical use may only be relevant
to some selected cases.
There was no evidence for an increase in CSF NfHSMI35 levels in pa-Stroke biomarkers 14
tients with ischaemic strokes. There are two potential reasons for this neg-
ative ﬁnding. Firstly, the location of the stroke may have been too rostral
to have been reﬂected in lumbar CSF. However, after reviewing all brain
scans, CSF NfHSMI35 levels were similar in those patients with predomi-
nantly cortical to those with predominantly subcortical infarcts (data not
shown). CSF NfHSMI35 levels showed a weak correlation with the modi-
ﬁed Rankin scale at discharge. This may be a spurious statistical ﬁnding
because CSF NfHSMI35 levels remained within the normal reference range
(Tables 2 and 3). Furthermore, the signiﬁcance of the ﬁnding was lost af-
ter correcting for the time delay between the stroke and the LP. Likewise
the slightly higher serum NfHSMI35 levels in the control group compared to
the ischaemic stroke patients may be due to an intravenous ﬂuid related
dilution effect in the stroke patients.
An intriguing new ﬁnding of this study was that the higher CSF S100B
levels in patients with an ischaemic cardio–embolic stroke compared to
those with large- or small–vessel disease were independent from stroke
volume. Our results therefore suggest that the damage to the CNS may
either be more widespread, more diffuse than shown by routine T2W brain
imaging or the consequence of ongoing micro–embolic infarctions. Inter-
estingly, a recent study on S100B in patients with dilated cardiomyopathy
found the mean serum levels to be about 4–times higher in patients (0.017Stroke biomarkers 15
ng/mL) compared to controls (0.051 ng/mL, p<0.01).35 Inspection of the
raw data in Figure 2 in reference35 shows that this was due to a clus-
ter of seven of the 21 cardiomyopathy patients having serum S100B levels
above 0.1 ng/mL. Based on a weak correlation of serum S100B with the N-
terminal portion of the brain natriuretic peptide pro-hormone (NT-proBNP)
it is suggested that serum S100B may be of cardiac origin, but the au-
thors are careful not to exclude the possibility of the brain parenchyma
being an alternative source. Our data on CSF instead of serum S100B
levels suggests that at least in our study S100B is released from the brain
parenchyma. Additionally the correlation between S100B and NT-proBNP
is not entirely convincing. Inspection of the raw data in Figure 3 in refer-
ence35 shows that these seven cardiomyopathy patients with high serum
S00B levels were spread across the whole range of NT-proBNP with some
of the highest S100B values being actually in the lower NT-proBNP range,
with no such correlation in the control group. Because of the epidemi-
ological demonstrated association between cardiomyopathy with arterial
ﬁbrillation (AF) and cardio–embolic stroke the present ﬁnding of higher
CSF S100B levels in patients with cardio–embolic stroke need to be inves-
tigated further. A limitation is that neither the present study nor the study
by Mazzini et al.35 did include any data on AF. Another limitation is the
small number in the present study with only 9 of the 33 stroke patients suf-Stroke biomarkers 16
fering from a cardio–embolic stroke. Based on our data 28 patients with
a stroke due to cardio–embolic aetiology or small–vessel disease need
to be recruited in any future study to reach a power of 80% (alpha 0.05)
to test this hypothesis. Diffusion weighted imaging which is more sensi-
tive than T2W imaging may also be of help in future studies to address
this question. Cardio–embolic stroke accounts for about 19% of ischaemic
strokes.36 As secondary stroke prevention continues to evolve37 , it may be
interesting to measure blood S100B levels prospectively, alongside blood
glucose, cholesterol, etc. in the longitudinal follow–up of these patients.
The correlation of CSF S100B levels with infarct volume is consistent to
that described for serum S100B levels.20,22 Likewise the correlation of
CSF S100B levels with stroke severity on admission is in line with previ-
ous results on serum S100B levels.20,22
Consistent with our previous data on patients with traumatic brain in-
jury and subarachnoid haemorrhage,14 yet again there was no correlation
between the CSF and serum levels of S100B. Likewise there was no cor-
relation between CSF and serum NfHSMI35 levels. The most likely reason
for a lack of a linear correlation is that the biological half–life of S100B and
NfHSMI35 differs between the CSF and the blood. The physiological “wash–
out” pattern of these two protein biomarkers from the CSF compartment in
the serum is not known. From the perfusion study in melanoma patientsStroke biomarkers 17
by Ghanem et al.38 we know that the half–life of S100B in the serum is
about 30 minutes. This is considerably shorter then the half life of S100B
in the CSF of 2 to 3 days observed in subarachnoid haemorrhage or 1 to 2
days in intracranial haemorrhage (Figure 1 in reference14). The half–life of
S100B in the CSF in patients with stroke is not known. Additionally the sit-
uation may be complicated by the development of secondary brain injury
or persistent astrocytic activation which may cause a secondary increase
of CSF S100B levels.39 New insight in dynamics of these processes can
be gained using microdialysis which allows for frequent sampling of extra-
cellular ﬂuid (ECF) from the brain parenchyma. Our own experience is that
ECF S100B raises rapidly in response to raise of intracranial pressure or
cerebral vasospasm.40 The data also shows that the half–life of S100B in
the ECF is less then one hour. The present study does not explain how
these protein biomarkers are “washed–out” it makes the important point
that there was no linear correlation which in all likelihood also applies to
other protein biomarkers currently investigated in the blood of stroke pa-
tients.
Further limitations of our study are the relatively young median age
of our patients, and their low NIHSS on admission. Although we did not
ﬁnd a correlation between the biomarker levels and the time delay to CSF
or serum collection, we cannot exclude that this may have inﬂuenced theStroke biomarkers 18
described relationships. Future longitudinal studies may enable this caveat
to be addressed.
Another important limitation of the present study is that the median de-
lay from onset of the ischaemic stroke to sampling time was relatively long,
with a median of 3 days and a range of up to 15 days. This is considerably
longer than that achieved in studies on serum S100B levels with 3 hours,32
5 hours,19 6 hours,20 8 hours21 or 24 hours22 in some of the more recent
studies. Given the previously–described wash–out pattern of S100B from
the CSF into the blood14 , one would expect to ﬁnd higher CSF S100B
levels during the ﬁrst hours following the ischaemic stroke. Therefore this
study does not rule out very early rises in S100B as a good indicator of the
amount of primary brain injury and thus its use as an important prognostic
indicator. Additionally, this study is weakened by the collection of samples
at different time points following the stroke. Given the well established
longitudinal proﬁle for serum S100B levels19–22,32,33 , one would be hesi-
tant to generalise from the present data. However, serial CSF sampling
in ischaemic stroke is not feasible. We do not believe that CSF sampling
will have a major place in the diagnostic workup of most ischaemic stroke
patients. However, the present result showing a lack of correlation be-
tween CSF and serum biomarker levels in stroke is important for future
biomarker studies from the blood. It suggests that future studies on serumStroke biomarkers 19
biomarkers need to be conducted longitudinally, ideally in short time inter-
vals, in order to account for the unknown release and wash out pattern of
biomarkers from the brain parenchyma following an ischaemic stroke.
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Table 1: Characteristics of the patients. For aetiology of the is-
chaemic stroke in patients labeled as “other” see main text.
Characteristic Median / % Range / number
Age (years) 53 33–79
Gender (F:M) 48% : 52% 16:17
Time from CVA to LP (days) 3 1–15
NIHSS score
on admission 4 0–13
at discharge 1 0–11
modiﬁed Rankin score
at discharge 2 0–5
Aetiology
cardiac 26% 9/33
large–vessel disease 11% 4/33





Middle cerebral 52% 17/33




Infarct volume (cm3) 4 0–78
CSF
Total protein (g/L)1 0.43 0.27–1.53
Qalb 6.6 3.9 - 28.6
White cell count mm3 1 0 - 23
Red cell count mm3 10 0 - 2768
1Reference range 0.15–0.45 mg/LStroke biomarkers 26
Table 2: CSF and serum levels of S100B [ng/mL] and
NfHSMI35 [ng/ml] and CSF ferritin [ng/mL] levels in patients with
an ischaemic stroke and the control cohort. N.S. = not signiﬁ-
cant.The median (IQR) is shown.
Biomarker [ng/mL] Controls Stroke p–value
CSF S100B median (range) 0.62 (0.51–0.70) 1.00 (0.62–1.52) <0.01
Serum S100B median (range) 0.01 (0.00–0.03) 0.09 (0.07–0.11) <0.0001
CSF NfHSMI35 median (range) 0.20 (0.09–0.24) 0.10 (0.07–0.16) N.S.
Serum NfHSMI35 median (range) 0.06 (0.00–0.26) 0.00 (0.00–0.15) p<0.05
CSF ferritin median (range) 2.34 (1.59–3.45) 10.0 (6.0–15.0) p<0.0001Stroke biomarkers 27
Table 3: CSF levels of S100B, NfHSMI35 and ferritin in patients
with an ischaemic stroke and the respective, previously published
reference populations.14,29,31 Levels above the published upper
reference limit are indicated as ’high’ and levels within the refer-
ence range as ’normal’. N.S. = not signiﬁcant (two–sided Fisher’s
exact test).
Reference population Stroke patients Signiﬁcance
S100B high2 4 (1%) 27 (82%)
S100B normal 405 (99%) 6 (18%) p<0.0001
NfHSMI35 high3 20 (5%) 2 (7%)
NfHSMI35 normal 396 (95%) 27 (93%) N.S.
Ferritin high4 20 (5%) 11 (39%)
Ferritin normal 386 (95%) 17 (61%) p<0.0001
2The upper reference limit of 0.55 ng/mL was 99th percentile of the cumulative fre-
quency of the results from 409 patients (233 female, 176 male) with a mean age of 46
years (range 20 to 99 years).14
3The upper reference limit of 0.73 ng/mL was 95th percentile of the cumulative fre-
quency of the results from 416 patients (242 female, 166 male, 8 without gender informa-
tion) with a mean age of 42 years (interquartile range 31.2–5.8 years).29
4The upper reference limit of 12 ng/mL was determined as the 95th percentile of the


























Figure 1: CSF S100B levels [ng/mL] in patients with stroke due to cardio–
embolic (CE), small–vessel (SV) or large–vessel (LV) aetiology. The
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Figure 2: The stroke volume (logarithmic scale) correlated with (A) the
NIHSS on admission (R=0.50, p<0.01) and (B) the CSF S100B levels
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Figure 3: Stroke severity on admission (NIHSS) correlated with CSF
S100B levels (R=0.56, p<0.001).